Bevacizumab-related Remote Intracranial Hemorrhages After Glioma Resection: A Cautionary Note Regarding the “Safe” Cessation Period

Gabriel Lee, Irina Kurowski,Anna K Nowak,Jolandi Van Heerden,Omprakash Damodaran

Neurosurgery Quarterly（2014）

引用 1|浏览8

暂无评分

摘要

Vascular endothelial growth factor (VEGF) is an important mediator of normal and pathologic angiogenesis. Anti-VEGF therapy such as bevacizumab (BV) has shown promise in the treatment of recurrent glioblastoma multiforme and other solid tumors. It is recommended that BV therapy should be stopped at

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要